We investigated the quantification of Ki-67 staining using digital image analysis (IA) as a complementary prognostic factor to the modified National Institutes of Health (NIH) classification in patients with gastrointestinal stromal tumor (GIST). We examined 92 patients, focusing on the correlation between age, sex, primary tumor site, tumor size, predominant histologic type, mitotic index, modified NIH classification (low/intermediate vs high), Ki-67 quantitation, and recurrence-free survival (RFS). We compared two IA processes for whole slide imaging (WSI) and manually captured image (MCI) methods. A Ki-67 quantitation cutoff was determined by receiver operator characteristics curve analysis. In the survival analysis, the high-risk group of a modified NIH classification, a mitotic count >5 per 20 high-powered fields, and Ki-67 cutoffs of !6% and !8% obtained by IA of the WSI and MCI methods, respectively, had an adverse impact on RFS. On multivariate analysis, each Ki-67 quantitation method strongly predicted prognosis, more strongly than the modified NIH classification. In addition, Ki-67 quantitation using IA of the MCI method could stratify low or intermediate risk and high risk GIST patients. Thus, IA is an excellent tool for quantifying Ki-67 to predict the prognosis of GIST patients, and this semiautomated approach may be preferable for patient care.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. They occur most frequently in the stomach and to a lesser extent in the small intestine, colon, and sites outside the gastrointestinal tract, such as the omentum and mesentery. 1 Accurate risk stratification is important for predicting the biological behavior of tumors and selecting an appropriate therapy because some patients develop recurrence and/or metastasis after complete resection. 2 A modified National
Institutes of Health (NIH) risk classification system that considers tumor location and size and mitotic count is presently used to identify patients with high-risk GIST that would benefit from adjuvant therapy. 3 However, this classification system needs to be improved or supplemented with a complementary index because even patients at low or intermediate risk may develop metastases and/or die and patients at high risk may survive for a long time.
Ki-67 immunohistochemistry is often used as a surrogate marker of proliferation and has become one of the most important parameters for grading and prognosis determination of a variety of tumors, including brain and soft tissue tumors and breast cancer. [4] [5] [6] Many researchers have investigated the suitability of manual counting of Ki-67 staining for prognostic classification of GIST. [7] [8] [9] [10] Whole slide imaging (WSI) with automated digital image analysis (IA) has also been used to quantify Ki-67 levels in GIST. [11] [12] [13] In this study, we compared clinicopathological parameters, including Ki-67 quantitation and recurrence-free survival (RFS), in GIST patients using Ki-67 quantitation by IA of both WSI and manually captured images (MCIs) on glass slides and attempted to identify patients with increased risk of metastasis and recurrence on the basis of their Ki-67 quantitation.
MATERIALS AND METHODS

Patient information
We examined 92 tumor specimens from 92 patients with GIST diagnosed in the Department of Surgical Pathology, Sapporo Medical University between 1998 and 2015. The inclusion criteria were as follows: a confirmed pathologic diagnosis of GIST; previous R0 resection; no imatinib therapy before or after surgery until recurrence; and availability of complete clinicopathologic and follow-up data.
This study was approved by the Institutional Review Board at Sapporo Medical University Hospital (No. 282-7). All patients who participated consented to the use of their tissue/data in this research.
Ki-67 immunohistochemistry
Tumor slides for all patients were stained with hematoxylin and eosin and reviewed, and representative sections from formalin-fixed, paraffin-embedded tissue blocks were examined using automated immunohistochemistry systems. The sections were loaded into a PT Link module (Dako, Carpinteria, CA, USA) and then transferred to an Autostainer Link 48 instrument (Dako). Immunostaining was performed using the primary mouse Ki-67 monoclonal antibody (clone MIB-1; ready-to-use, FLEX, Dako) and the Envision FLEX detection system (Dako).
Image analysis
We first selected one analysis area corresponding to a "hot spot" on a Ki-67-stained slide by optical microscopy and marked a 5 mm-sized circle with a marker pen before the IA. The area almost wholly consisted of GIST cells without contamination from smooth muscle cells of the muscularis propria and inflammatory infiltrates.
The first WSI method for Ki-67 quantitation involved automatic quantification of the area within the circle of the scanned Ki-67 image by WSI (NanoZoomer 2.0-HT; Hamamatsu Photonics, Hamamatsu, Japan) using an IA algorithm (Tissue Studio; Definiens AG, M€ unchen, Germany). 6, 12 The alternative MCI method involved the selection of a "hot spot" Ki-67 image with a microscope digital camera in real time at Â200 magnification within the circle described above and quantification of the MCI by IA software (Patholoscope; Mitani Corp, Tokyo, Japan), with the parameters set in advance for Ki-67 staining in our institution; the count images for each case were reviewed to verify the accuracy of the IA quantitation ( Fig. 1) . In most cases, the expected results were obtained in one analytic process.
Statistical analysis
We performed statistical analyses using SPSS Statistics version 24 (IBM Corp, Armonk, NY, USA) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). To obtain the Ki-67 cutoff with the highest sensitivity and specificity, 10 a receiver operator characteristics (ROC) curve was analyzed for tumor recurrence using EZR. Recurrence-free survival was defined as the time interval between the date of surgery and the date of GIST recurrence or last follow-up. Prognostic value was examined for age (<70 vs !70 years), sex (male vs female), primary tumor site (stomach vs non-stomach), tumor size ( 5 cm vs >5 cm), predominant cell type (spindle cell vs epithelioid), mitotic count ( 5 vs >5 per 20 high-powered fields [HPFs; 5 mm 2 ]; Nikon CFI 10X/22, Tokyo, Japan), risk stratification by modified NIH criteria (low or intermediate risk vs high risk), 3 and Ki-67 (<6% vs !6% and <8% vs !8%) as described below. Survival analyses were performed using Kaplan-Meier methods, and survival between the groups was compared by stratified and unstratified logrank tests. A stepwise Cox proportional hazards model was used for multivariate analysis of the factors associated with RFS. A P-value < 0.05 was considered to be statistically significant.
RESULTS
Clinical characteristics
The 92 patients in this study comprised 33 men (35.9%) and 59 women (64.1%) with a mean age of 66. 
Histologic features and Ki-67 quantitation
To avoid contamination from smooth muscle cells of the muscularis propria and inflammatory infiltrates, we carefully selected areas that mainly included GIST cells with minimal contamination from preexisting cells in the background. Eighty-eight (95.7%) of the GISTs were predominantly of the spindle cell type and 4 (4.3%) were predominantly epithelioid. The spindle cell-type tumors were characterized by a proliferation of uniform spindle cells forming interlacing bundles, whorls, or a storiform pattern, with a varying amount of interstitial collagen. The neoplastic cells had an 5%) and >5 per 20 HPFs in 6 cases (6.5%). The Ki-67 quantitation ranged from 0% to 38% (mean 5.2%, median 3.0%) by IA of the WSI method and from 0% to 46% (mean 7.6%, median 4.5%) by IA of the MCI method. As shown in Figure 1 , the IA almost fully distinguished positive and negative tumor cells. When a few tumor cells were miscategorized, we were able to manually make corrections using the count images obtained with the MCI method.
Statistical analysis
On ROC curve analysis, the optimum cutoffs for Ki-67 quantitation obtained by IA of the WSI and MCI methods were 6% (sensitivity 64.3%, specificity 80.5%) and 8% (sensitivity 76.9%, specificity 75.6%), respectively.
In the survival analysis, the modified NIH classification of high-risk GIST (P ¼ 0.05), a mitotic count above 5 per 20 HPFs (P ¼ 0.002), Ki-67 !6% (P ¼ 0.001), and Ki-67 !8% (P ¼ 0.001) had an adverse impact on RFS (Table 1) .
On multivariate analysis, Ki-67 !6% (hazard ratio 5.62; 95% confidence interval 1.82-17.37; P ¼ 0.003) and Ki-67 !8% (hazard ratio 5.14; 95% confidence interval 1.53-17.33; P ¼ 0.008) were independent predictors of RFS (Table 1) .
We then examined the prognostic value of the Ki-67 quantification obtained by IA of the WSI and MCI methods in cases stratified according to the modified NIH classification (Fig. 2) . On stratified analysis, Ki-67 !6% had an adverse impact on RFS in high-risk group patients (P ¼ 0.001). However, Ki-67 !6% had no adverse impact on RFS in low-and intermediate risk group patients (P ¼ 0.18). In contrast, Ki-67 !8% had an adverse impact on RFS in both high-risk (P ¼ 0.028) and low and intermediate risk (P ¼ 0.017) group patients.
DISCUSSION
This is the first study to use two different IA processes involving WSI and MCI methods to examine the prognostic value of Ki-67 quantitation in patients with GIST. Our study showed that either method of IA quantitation of Ki-67 staining strongly predicted prognosis, better than the modified NIH classification. In addition, Ki-67 quantitation using IA of the MCI method could stratify low or intermediate risk and high risk GIST patients. The patient prognosis of gastric GIST is better than that of non-gastric GIST, such as that of the small intestine. Here, the tumor site tended to be associated with RFS in survival analysis, although Ki-67 quantitation between gastric and non-gastric GISTs was not markedly different in this study (data not shown).
The differences in the Ki-67 quantitation results between the two IA processes for the same Ki-67-stained slide may be due to differences in the IA algorithm. The IA software of the MCI method has some merits. First, this software is equipped with a proprietary algorithm to count weakly negative nuclei or overlapping cells with a high level of precision. In a previous study, 12 we found that the intensity of Ki-67 staining in GIST varied greatly among institutions, resulting in differences in Ki-67 quantitation determined by IA of the WSI method between the institutes. Second, to handle such different staining methods and diagnostic criteria among institutions, parameters can be set individually for each facility. Third, this software can be linked to a variety of microscope digital cameras; the analytic process requires real time viewing of microscope images. In addition, the validation process of the count images reviewed by pathologists was shown in this study to contribute to accurate Ki-67 quantitation by IA, in keeping with the concept proposed by Farris et al., 14 which was an effective complementation of the modified NIH criteria in predicting the prognosis of all GIST patients. Finally, the IA software of the MCI method is costeffective compared with automated IA systems for the WSI method and provides an easy approach to Ki-67 quantitation in daily clinical practice. It thus permits standardization of the assessment of the prognostic immunohistochemical markers in each institute and brings us one step closer to personalized patient care.
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